[Pharmacogenetics/pharmacogenomics in psychiatry].
Pharmacogenetics/pharmacogenomics has been developed so rapidly in these twenty years and the pharmacogenetic/pharmacogenomic research in psychiatry is also the case. Especially, the impact of genetic polymorphism (e.g., cytochrome P450 (CYP)) on pharmacokinetics of psychotropics have been extensively studied, however, recently, most of the studies in this field have been moved to pharmacodynamic study, i.e., the studies on impact of genetics polymorphism on clinical response and adverse effects to pharmacotherapy with psychotropics. Development of pharmacogenetics/ pharmacogenomics in psychiatry may well lead to a future of individualized pharmacotherapy for psychiatric disorders.
Ueda
Mikito
M
Department of Psychiatry, Dokkyo Medical University School of Medicine.
Ishiguro
Shin
S
Watanabe
Takashi
T
Saeki
Yoshinori
Y
Shimoda
Kazutaka
K
D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D004361:Drug Tolerance / Q000235:genetics; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D057285:Precision Medicine; D011570:Psychiatry; D011619:Psychotropic Drugs; D044469:Racial Groups; D017981:Receptors, Neurotransmitter / Q000235:genetics; D011985:Receptors, Serotonin / Q000235:genetics; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics; D014365:Tryptophan Hydroxylase / Q000235:genetics
D019208:Brain-Derived Neurotrophic Factor; D011619:Psychotropic Drugs; D017981:Receptors, Neurotransmitter; D011985:Receptors, Serotonin; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins; C069474:glutamine receptor; D003577:Cytochrome P-450 Enzyme System; D014365:Tryptophan Hydroxylase